Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Octopus Biosafety's Enterprise Value for the quarter that ended in Dec. 2024 was €2.30 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Octopus Biosafety's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was €-0.84 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Octopus Biosafety EV-to-EBIT Related Terms
Octopus Biosafety EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Octopus Biosafety's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:OCR vs DELL, ANET, SNDK: EV-to-EBIT Comparison
For the Computer Hardware subindustry, Octopus Biosafety's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Octopus Biosafety EV-to-EBIT vs Hardware Industry
For the Hardware industry and Technology sector, Octopus Biosafety's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Octopus Biosafety's EV-to-EBIT falls into.
Octopus Biosafety's current Enterprise Value is €17.05 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Octopus Biosafety's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was €-0.84 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Octopus Biosafety (STU:OCR) has a EV-to-EBIT of -20.37 as of Aug. 16, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Octopus Biosafety and its competitors. According to the industry distribution chart, Octopus Biosafety ranks #999999 out of 1774 companies in the Hardware industry.
Is Octopus Biosafety's EV-to-EBIT too high?
Octopus Biosafety's current EV-to-EBIT is -20.37. Based on the distribution chart, Octopus Biosafety ranks #999999 out of 1774 companies in the Hardware industry, which is in the bottom quartile relative to peers. Overall, Octopus Biosafety has a GF Score™ of 5/100, reflecting its overall financial health beyond just this single metric.
How does Octopus Biosafety's EV-to-EBIT compare to DELL and ANET?
According to the Hardware industry distribution chart, Octopus Biosafety ranks #999999 out of 1774 companies for EV-to-EBIT. This places Octopus Biosafety in the lower half of its industry. The industry median EV-to-EBIT is 21.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Hardware company?
The median EV-to-EBIT among Hardware companies is 21.20, based on 1,774 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Octopus Biosafety and its competitors. For the Hardware industry, the median EV-to-EBIT is 21.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Octopus Biosafety's current EV-to-EBIT is -20.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Octopus Biosafety stock overvalued right now?
Octopus Biosafety (STU:OCR) has a current EV-to-EBIT of -20.37. The stock's GF Value™ is €0.08, compared to a current price of €0.13 — trading 62.5% above its estimated fair value. The current EV-to-EBIT is -20.37. Octopus Biosafety's overall GF Score™ is 5/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Octopus Biosafety (STU:OCR), the current EV-to-EBIT is -20.37 as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Octopus Biosafety (STU:OCR) Overvalued in 2026?
Based on GuruFocus' analysis, Octopus Biosafety stock appears to be overvalued.
The current stock price of €0.13 is trading 62.5% above its estimated GF Value™ of €0.08.
Key valuation signals for STU:OCR:
EV-to-EBIT: -20.37
GF Value™: €0.08 vs. price of €0.13 (62.5% above fair value)
No single metric tells the full story. See the STU:OCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Octopus Biosafety is engaged in the design, manufacture and marketing of mobile, autonomous, intelligent and modular robots for use in Agro-food sector, Healthcare sector, Defense sector, Civil Protection sector, and Surveillance and Transport sector.
5GF Score
Get the complete analysis for STU:OCR
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:OCR has been successfully added to your 
